Concretely: cagrilintide · twenty-one days.
I would like to understand the steps well enough to explain them to someone else.
I have access to a refrigerator with a logger and a freezer without one, which may be relevant.
So: what is the actual procedure, and which steps matter as opposed to being ritual?
21 days past a due dose is 3 half-lives at the seven-day half-life this class runs on, which leaves about 12.5 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(21÷7) = 0.125. At 12.5 per cent the exposure has largely washed out — and the tolerability that the escalation bought washes out with it, which is precisely what a ladder reset exists to protect against. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.
The relevant arithmetic is that one missed dose of a weekly agent produces a trough about half the usual, which is well inside the normal range.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
| Week | Fraction of steady state | Trough as × dose |
|---|---|---|
| 1 | 50 % | 0.50 |
| 2 | 75 % | 0.75 |
| 3 | 88 % | 0.88 |
| 4 | 94 % | 0.94 |
| 5 | 97 % | 0.97 |
| 6 | 98 % | 0.98 |
This is why a four-week step interval is approximately, but not exactly, steady state.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
Published missed-dose guidance for the weekly agents in this class specifies a window of about five days, derived directly from the half-life.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStated carefully, this is one of the questions where the pharmacokinetics gives a reassuring answer and the anxiety persists anyway.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
Worth being precise here: one missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
Never double up. Peak exposure is what drives the symptoms.
The honest answer is that a single missed weekly dose is not an event, and that two in a row starts to matter.
Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.
The part that matters: to change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Repeated missed doses are a different problem from an occasional one and should be treated as such.
Set a recurring reminder attached to something you already do weekly.
Answering this needs the agent, since the answer for a thirteen-hour half-life and a one-week half-life are entirely different.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
Peak exposure rather than average exposure drives gastrointestinal tolerability, which is the reason doubling up is advised against.
A published missed-dose window applies to a licensed product with a known content, which unverified material is not.
Two or more missed weekly doses means considering a lower restarting step.
Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.
The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
Nothing here is medical advice, and research-use compounds are not approved for human use.
To move your dosing day, move it later and keep three days between doses.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.